Insiders Are Still Scooping Up Under Armour and WR Berkley Shares
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
Headquartered in Alameda, CA Fiscal year ends December NASDAQ: VANI vivani.com
Vivani Medical, Inc. (Nasdaq: VANI), formerly Second Sight Medical Products, is a clinical-stage biopharmaceutical and medical device company with no commercial revenue. It operates two divisions.
- **Biopharm Division:** Uses the proprietary NanoPortal platform to develop miniature, ultra-long-acting subdermal drug implants. The implants are designed for once- or twice-yearly administration, aiming to improve medication adherence and tolerability. They can also be removed when therapy needs to stop. The lead candidate is NPM-139, a semaglutide (GLP-1) implant for chronic weight management, and the company is building a portfolio of GLP-1 implants for obesity and type 2 diabetes. NPM-139 recently reported positive Phase 1 (SLIM-1) top-line data, and a Phase 2 dose-ranging weight maintenance trial is planned for 2027. Novo Nordisk is evaluating NPM-139 under a non-exclusive agreement.
- **Neurostimulation Division:** Conducted through wholly owned subsidiary Cortigent, which develops brain implant neurostimulation devices. Its products include the Orion cortical stimulation system for blindness, which has FDA Breakthrough Device designation. Cortigent is also developing technology for arm and hand motor recovery after stroke. The predecessor company previously marketed the FDA-approved Argus II retinal prosthesis. Cortigent is pending a merger with Nasdaq-listed ClearOne that would make it a standalone public company under the ticker CRGT. Updated
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
The CEO of GameStop just picked up a million shares, and insiders are returning for more shares of Under Armour, Mission Produce, and more.
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
Vivani Medical, Inc. (Nasdaq: VANI), formerly Second Sight Medical Products, is a clinical-stage biopharmaceutical and medical device company with no commercial revenue.
The Wall Street consensus 12-month price target for VANI is $3.83.